Penetration of imipenem and cilastatin into cerebrospinal fluid of patients with bacterial meningitis

The penetration of imipenem and cilastatin into the cerebrospinal fluid (CSF) was determined in patients with bacterial meningitis. Four 1000 mg doses [corrected] of both imipenem and cilastatin were infused intravenously over 20-30 min at 6 h intervals, first between days 2 and 4, and again, whenev...

Full description

Saved in:
Bibliographic Details
Published in:Journal of antimicrobial chemotherapy 1985-12, Vol.16 (6), p.751-755
Main Authors: MODAI, J, VITTECOQ, D, DECAZES, J. M, MEULEMANS, A
Format: Article
Language:English
Subjects:
Adult
Aged
Antibacterial agents
Antibiotics. Antiinfectious agents. Antiparasitic agents
Bacterial Infections - cerebrospinal fluid
Bacterial Infections - drug therapy
Biological and medical sciences
Cilastatin
Cyclopropanes - cerebrospinal fluid
Cyclopropanes - therapeutic use
Female
Humans
Imipenem
Male
Medical sciences
Meningitis - cerebrospinal fluid
Meningitis - drug therapy
Middle Aged
Pharmacology. Drug treatments
Thienamycins - cerebrospinal fluid
Thienamycins - therapeutic use
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The penetration of imipenem and cilastatin into the cerebrospinal fluid (CSF) was determined in patients with bacterial meningitis. Four 1000 mg doses [corrected] of both imipenem and cilastatin were infused intravenously over 20-30 min at 6 h intervals, first between days 2 and 4, and again, whenever possible, between days 11 to 20, in 12 patients with bacterial meningitis undergoing treatment with other antibiotics. Concentrations of imipenem and cilastatin in serum and cerebrospinal fluid samples obtained either at 60, 90 or 120 min following the fourth dose were measured by high pressure liquid chromatography. Concentrations of imipenem in CSF ranged from 0.5 to 11 mg/1 and concentrations of cilastatin ranged from 1.1 to 10.5 mg/1, depending on the sampling time and the time elapsed since the onset of the disease.
ISSN:0305-7453
1460-2091